Immunosuppression Armamentarium in 2010: Mechanistic and Clinical Considerations

Pediatric Clinics of North America

Volumn 57, Issue 2, 2010, Pages 433-457

  Urschel, Simon ^a,b   Altamirano Diaz, Luis A ^b   West, Lori J ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Immunosuppressive treatment; Induction; Maintenance immunosuppression; Mechanism of action; Pediatric transplantation; Side effects; Solid organ transplantation

Indexed keywords

ABATACEPT; ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN; DACLIZUMAB; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MURONOMAB; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACNE; ACUTE GRAFT REJECTION; ALOPECIA; ANAPHYLAXIS; ANEMIA; APHTHOUS ULCER; AUTOIMMUNE HEMOLYTIC ANEMIA; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; CATARACT; CHRONIC DISEASE; CLINICAL TRIAL; CUSHINGOID SYNDROME; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG WITHDRAWAL; EDEMA; EMOTIONAL DISORDER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GLOMERULONEPHRITIS; GRAFT REJECTION; GRAFT SURVIVAL; GROWTH DISORDER; GROWTH RETARDATION; HEALING IMPAIRMENT; HEART TRANSPLANTATION; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MEGALOBLASTIC ANEMIA; NEPHROTOXICITY; NEUROTOXICITY; ORGAN TRANSPLANTATION; OSTEOPENIA; PANCREATITIS; PERIPHERAL NEUROPATHY; PHARMACOLOGICAL BLOCKING; PNEUMONIA; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SODIUM RETENTION; SURVIVAL TIME; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; TREMOR; WATER RETENTION; WEIGHT GAIN;

CHILD; DRUGS, INVESTIGATIONAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION;

EID: 77950965578     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2010.01.018     Document Type: Review

References (113)

1. Martz K, Stablein DM. NAPRTCS 2008 Annual Report. In: North American Pediatric Renal Trials and Collaborative Studies; 2008.
2. Kirk R., Edwards L.B., Aurora P., et al. Registry of the International Society for Heart and Lung Transplantation: Twelfth Official Pediatric Heart Transplantation Report-2009. J Heart Lung Transplant 2009, 28(10):993-1006.
3. Aurora P., Edwards L.B., Christie J.D., et al. Registry of the International Society for Heart and Lung Transplantation: Twelfth Official Pediatric Lung and Heart/Lung Transplantation Report-2009. J Heart Lung Transplant 2009, 28(10):1023-1030.
4. Ng V.L., Fecteau A., Shepherd R., et al. Outcomes of 5-year survivors of pediatric liver transplantation: report on 461 children from a North American multicenter registry. Pediatrics 2008, 122(6):e1128-e1135.
5. Pillai A.A., Levitsky J. Overview of immunosuppression in liver transplantation. World J Gastroenterol 2009, 15(34):4225-4233.
6. Kawai T., Cosimi A.B., Spitzer T.R., et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008, 358(4):353-361.
7. Brennan D.C., Flavin K., Lowell J.A., et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999, 67(7):1011-1018.
8. Brophy P.D., Thomas S.E., McBryde K.D., et al. Comparison of polyclonal induction agents in pediatric renal transplantation. Pediatr Transplant 2001, 5(3):174-178.
9. Carlsen J., Johansen M., Boesgaard S., et al. Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection. J Heart Lung Transplant 2005, 24(3):296-302.
10. Chin C., Pittson S., Luikart H., et al. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab. Transplantation 2005, 80(4):477-481.
11. Ciancio G., Burke G.W. Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant 2008, 8(1):15-20.
12. Kirk A.D., Cherikh W.S., Ring M., et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007, 7(11):2619-2625.
13. Pescovitz M.D. Use of antibody induction in pediatric renal transplantation. Curr Opin Organ Transplant 2008, 13(5):495-499.
14. Pollock-BarZiv S.M., Allain-Rooney T., Manlhiot C., et al. Continuous infusion of thymoglobulin for induction therapy in pediatric heart transplant recipients; experience and outcomes with a novel strategy for administration. Pediatr Transplant 2009, 13(5):585-589.
15. Tan H.P., Donaldson J., Ellis D., et al. Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience. Transplantation 2008, 86(12):1725-1731.
16. Yamani M.H., Taylor D.O., Czerr J., et al. Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study. Clin Transplant 2008, 22(1):76-81.
17. Vilalta R., Lara E., Madrid A., et al. Delayed graft function is reduced with antithymocyte globulin induction in pediatric kidney transplantation. Transplant Proc 2009, 41(6):2373-2375.
18. Delgado D.H., Miriuka S.G., Cusimano R.J., et al. Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction. J Heart Lung Transplant 2005, 24(2):166-169.
19. Gustafsson F., Ross H.J. Renal-sparing strategies in cardiac transplantation. Curr Opin Organ Transplant 2009, 14(5):566-570.
20. Smith J.M., Stablein D.M., Munoz R., et al. Contributions of the Transplant Registry: the 2006 Annual Report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Pediatr Transplant 2007, 11(4):366-373.
21. Christie J.D., Edwards L.B., Aurora P., et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-Sixth Official Adult Lung and Heart-Lung Transplantation Report-2009. J Heart Lung Transplant 2009, 28(10):1031-1049.
22. Goland S., Czer L.S., Coleman B., et al. Induction therapy with thymoglobulin after heart transplantation: impact of therapy duration on lymphocyte depletion and recovery, rejection, and cytomegalovirus infection rates. J Heart Lung Transplant 2008, 27(10):1115-1121.
23. Issa N.C., Fishman J.A. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 2009, 48(6):772-786.
24. Bonnefoy-Berard N., Revillard J.P. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 1996, 15(5):435-442.
25. Mayes J.T., Thistlethwaite J.R., Stuart J.K., et al. Reexposure to OKT3 in renal allograft recipients. Transplantation 1988, 45(2):349-353.
26. Sgro C. Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Toxicology 1995, 105(1):23-29.
27. Lindenfeld J., Miller G.G., Shakar S.F., et al. Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs. Circulation 2004, 110(24):3734-3740.
28. Benfield M.R., Tejani A., Harmon W.E., et al. A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation. Pediatr Transplant 2005, 9(3):282-292.
29. Lan R.Y., Selmi C., Gershwin M.E. The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). J Autoimmun 2008, 31(1):7-12.
30. Wang Z., Shi B.Y., Qian Y.Y., et al. Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory T cells in kidney transplantation. Clin Exp Immunol 2009, 155(3):496-503.
31. Grundy N., Simmonds J., Dawkins H., et al. Pre-implantation basiliximab reduces incidence of early acute rejection in pediatric heart transplantation. J Heart Lung Transplant 2009, 28(12):1279-1284.
32. Hocker B., Kovarik J.M., Daniel V., et al. Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication. Transplantation 2008, 86(9):1234-1240.
33. Praditpornsilpa K., Avihingsanon Y., Kupatawintu P., et al. Monitoring of T-cell subsets in patients treated with anti-CD 25 antibody. Transplant Proc 2004, 36(2 Suppl 1):S487-S491.
34. Nashan B., Moore R., Amlot P., et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997, 350(9086):1193-1198.
35. Kahan B.D., Rajagopalan P.R., Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 1999, 67(2):276-284.
36. Nashan B., Light S., Hardie I.R., et al. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999, 67(1):110-115.
37. Bumgardner G.L., Hardie I., Johnson R.W., et al. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 2001, 72(5):839-845.
38. Sheashaa H.A., Bakr M.A., Ismail A.M., et al. Basiliximab induction therapy for live donor kidney transplantation: a long-term follow-up of prospective randomized controlled study. Clin Exp Nephrol 2008, 12(5):376-381.
39. Webster A.C., Playford E.G., Higgins G., et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2004, (1). CD003897.
40. Moller C.H., Gustafsson F., Gluud C., et al. Interleukin-2 receptor antagonists as induction therapy after heart transplantation: systematic review with meta-analysis of randomized trials. J Heart Lung Transplant 2008, 27(8):835-842.
41. Auphan N., DiDonato J.A., Rosette C., et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995, 270(5234):286-290.
42. Sgourakis G., Radtke A., Fouzas I., et al. Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl Int 2009, 22(9):892-905.
43. Pascual J., Zamora J., Galeano C., et al. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 2009, (1). CD005632.
44. Gras J.M., Gerkens S., Beguin C., et al. Steroid-free, tacrolimus-basiliximab immunosuppression in pediatric liver transplantation: clinical and pharmacoeconomic study in 50 children. Liver Transpl 2008, 14(4):469-477.
45. Sarwal M.M., Vidhun J.R., Alexander S.R., et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003, 76(9):1331-1339.
46. Klee C.B., Crouch T.H., Krinks M.H. Calcineurin: a calcium- and calmodulin-binding protein of the nervous system. Proc Natl Acad Sci U S A 1979, 76(12):6270-6273.
47. Liu J., Farmer J.D., Lane W.S., et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991, 66(4):807-815.
48. Borel J.F., Feurer C., Gubler H.U., et al. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976, 6(4):468-475.
49. Calne R.Y., White D.J., Evans D.B., et al. Cyclosporin A in cadaveric organ transplantation. Br Med J (Clin Res Ed) 1981, 282(6268):934-936.
50. Kino T., Hatanaka H., Miyata S., et al. FK-506, a novel immunosuppressant isolated from a streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987, 40(9):1256-1265.
51. Cummins C.L., Jacobsen W., Benet L.Z. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002, 300(3):1036-1045.
52. de Jonge H., Naesens M., Kuypers D.R. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit 2009, 31(4):416-435.
53. Cattaneo D., Baldelli S., Perico N. Pharmacogenetics of immunosuppressants: progress, pitfalls and promises. Am J Transplant 2008, 8(7):1374-1383.
54. Knight S.R., Morris P.J. The clinical benefits of cyclosporine C2-level monitoring: a systematic review. Transplantation 2007, 83(12):1525-1535.
55. Christians U., Jacobsen W., Benet L.Z., et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002, 41(11):813-851.
56. Tonshoff B., Hocker B. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Pediatr Transplant 2006, 10(6):721-729.
57. Webster A., Woodroffe R.C., Taylor R.S., et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005, (4). CD003961.
58. Haddad E.M., McAlister V.C., Renouf E., et al. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006, (4). CD005161.
59. Ye F., Ying-Bin X., Yu-Guo W., et al. Tacrolimus versus cyclosporine microemulsion for heart transplant recipients: a meta-analysis. J Heart Lung Transplant 2009, 28(1):58-66.
60. Fan Y., Xiao Y.B., Weng Y.G. Tacrolimus versus cyclosporine for adult lung transplant recipients: a meta-analysis. Transplant Proc 2009, 41(5):1821-1824.
61. Nankivell B.J., Borrows R.J., Fung C.L., et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003, 349(24):2326-2333.
62. Groetzner J., Kaczmarek I., Schulz U., et al. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Transplantation 2009, 87(5):726-733.
63. Sato K., Amada N., Sato T., et al. Severe elevations of FK506 blood concentration due to diarrhea in renal transplant recipients. Clin Transplant 2004, 18(5):585-590.
64. Krensky A.M., Clayberger C. Transplantation immunology. Pediatr Clin North Am 1994, 41(4):819-839.
65. Terhorst D., Drecoll U., Stockfleth E., et al. Organ transplant recipients and skin cancer: assessment of risk factors with focus on sun exposure. Br J Dermatol 2009, 161(Suppl 3):85-89.
66. Copeland J.G., Mammana R.B., Fuller J.K., et al. Heart transplantation. Four years' experience with conventional immunosuppression. JAMA 1984, 251(12):1563-1566.
67. Young C.J., Sollinger H.W. RS-61443: a new immunosuppressive agent. Transplant Proc 1994, 26(6):3144-3146.
68. Allison A.C., Eugui E.M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000, 47(2-3):85-118.
69. Kobashigawa J.A., Meiser B.M. Review of major clinical trials with mycophenolate mofetil in cardiac transplantation. Transplantation 2005, 80(2 Suppl):S235-S243.
70. Sollinger H.W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995, 60(3):225-232.
71. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996, 61(7):1029-1037.
72. Mathew T.H. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998, 65(11):1450-1454.
73. Knight S.R., Russell N.K., Barcena L., et al. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation 2009, 87(6):785-794.
74. Germani G., Pleguezuelo M., Villamil F., et al. Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil. Am J Transplant 2009, 9(8):1725-1731.
75. Remuzzi G., Cravedi P., Costantini M., et al. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol 2007, 18(6):1973-1985.
76. Cravedi P., Perna A., Ruggenenti P., et al. Mycophenolate mofetil versus azathioprine in organ transplantation. Am J Transplant 2009, 9(12):2856-2857.
77. Jungraithmayr T., Staskewitz A., Kirste G., et al. Pediatric renal transplantation with mycophenolate mofetil-based immunosuppression without induction: results after three years. Transplantation 2003, 75(4):454-461.
78. Jungraithmayr T.C., Wiesmayr S., Staskewitz A., et al. Five-year outcome in pediatric patients with mycophenolate mofetil-based renal transplantation. Transplantation 2007, 83(7):900-905.
79. Staskewitz A., Kirste G., Tonshoff B., et al. Mycophenolate mofetil in pediatric renal transplantation without induction therapy: results after 12 months of treatment. German Pediatric Renal Transplantation Study Group. Transplantation 2001, 71(5):638-644.
80. Benfield M.R., Symons J.M., Bynon S., et al. Mycophenolate mofetil in pediatric renal transplantation. Pediatr Transplant 1999, 3(1):33-37.
81. Kaczmarek I., Ertl B., Schmauss D., et al. Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil. J Heart Lung Transplant 2006, 25(5):550-556.
82. Meiser B., Kaczmarek I., Mueller M., et al. Low-dose tacrolimus/sirolimus and steroid withdrawal in heart recipients is highly efficacious. J Heart Lung Transplant 2007, 26(6):598-603.
83. Budde K., Knoll G., Curtis J., et al. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic). Clin Nephrol 2006, 66(2):103-111.
84. Kobashigawa J.A., Renlund D.G., Gerosa G., et al. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant 2006, 25(8):935-941.
85. Robaeys G., Cassiman D., Verslype C., et al. Successful conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic) in liver transplant patients with gastrointestinal side effects. Transplant Proc 2009, 41(2):610-613.
86. Darji P., Vijayaraghavan R., Thiagarajan C.M., et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders. Transplant Proc 2008, 40(7):2262-2267.
87. Merlob P., Stahl B., Klinger G. Tetrada of the possible mycophenolate mofetil embryopathy: a review. Reprod Toxicol 2009, 28(1):105-108.
88. Johnston A., He X., Holt D.W. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. Transplantation 2006, 82(11):1413-1418.
89. Kuypers D.R., Claes K., Evenepoel P., et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol 2003, 43(8):866-880.
90. Payen S., Zhang D., Maisin A., et al. Population pharmacokinetics of mycophenolic acid in kidney transplant pediatric and adolescent patients. Ther Drug Monit 2005, 27(3):378-388.
91. van Gelder T., Silva H.T., de Fijter J.W., et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008, 86(8):1043-1051.
92. Kamar N., Marquet P., Gandia P., et al. Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses. Ther Drug Monit 2009, 31(4):451-456.
93. Yang Q., Guan K.L. Expanding mTOR signaling. Cell Res 2007, 17(8):666-681.
94. Saemann M.D., Haidinger M., Hecking M., et al. The multifunctional role of mTOR in innate immunity: implications for transplant immunity. Am J Transplant 2009, 9(12):2655-2661.
95. Keogh A., Richardson M., Ruygrok P., et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004, 110(17):2694-2700.
96. Vezina C., Kudelski A., Sehgal S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975, 28(10):721-726.
97. Schachter A.D., Benfield M.R., Wyatt R.J., et al. Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy. Pediatr Transplant 2006, 10(8):914-919.
98. Kaplan B., Meier-Kriesche H.U., Napoli K.L., et al. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 1998, 63(1):48-53.
99. Huyghe E., Zairi A., Nohra J., et al. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview. Transpl Int 2007, 20(4):305-311.
100. Webster A., Pankhurst T., Rinaldi F., et al. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients. Cochrane Database Syst Rev 2006, (2). CD004756.
101. Webster A.C., Pankhurst T., Rinaldi F., et al. Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: a systematic review of randomized trial data. Transplantation 2006, 81(7):953-965.
102. Sarahrudi K., Estenne M., Corris P., et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. J Thorac Cardiovasc Surg 2004, 127(4):1126-1132.
103. Chan M.C., Kwok B.W., Shiba N., et al. Conversion of cyclosporine to tacrolimus for refractory or persistent myocardial rejection. Transplant Proc 2002, 34(5):1850-1852.
104. Everly J.J., Walsh R.C., Alloway R.R., et al. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant 2009, 14(6):662-666.
105. Stegall M.D., Gloor J.M. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant 2009, 15(1):8-10.
106. Flynn J.M., Byrd J.C. Campath-1H monoclonal antibody therapy. Curr Opin Oncol 2000, 12(6):574-581.
107. Ciancio G., Burke G.W., Gaynor J.J., et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008, 22(2):200-210.
108. Teuteberg J.J., Shullo M.A., Zomak R., et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplant 2010, 10(2):382-388.
109. McAdam A.J., Schweitzer A.N., Sharpe A.H. The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol Rev 1998, 165:231-247.
110. Suntharalingam G., Perry M.R., Ward S., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006, 355(10):1018-1028.
111. Vincenti F. Costimulation blockade in autoimmunity and transplantation. J Allergy Clin Immunol 2008, 121(2):299-306. [quiz: 7-8].
112. Vincenti F., Larsen C., Durrbach A., et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005, 353(8):770-781.
113. Vincenti F., Grinyo J.M., Charpentier B., et al. Primary outcomes from a randomized, phase III study of belatacept vs cyclosporine in kidney transplant recipients (BENEFIT study) 2009, American Transplant Congress, Boston.